Boom time for CROs?

Boom time for CROs?

The amount of pharmaceutical R&D funding headed out-of-house to
research suppliers engaged in drug development work will grow
almost 15 per cent annually for the next five years, nearly double
the anticipated increase in overall...

EU: Investment in R&D slipping

EU: Investment in R&D slipping

European scientists continue to be strong in areas such as medical
research and chemistry and Europe may produce the highest number of
science graduates but it is lagging behind in biotechnology, still
employs fewer researchers, accounts...


Follow us


View more


Featured Suppliers